Castle Biosciences Inc(CSTL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.65 | Insider Own | 2% | Shs Outstand | 30.5M | Perf Week | 16.03% |
| Market Cap | 1.18B | Forward P/E | - | EPS next Y | 24.93% | Insider Trans | -35.72% | Shs Float | 29.9M | Perf Month | 8.39% |
| Enterprise Value | 0.95B | PEG | - | EPS next Q | -0.35 | Inst Own | 91.38% | Short Float | 6.74% | Perf Quarter | 37.54% |
| Income | -0.02B | P/S | 3.29 | EPS this Y | -50% | Inst Trans | -0.61% | Short Ratio | 5.06 | Perf Half Y | 57.25% |
| Sales | 0.36B | P/B | 2.5 | EPS next 5Y | 25.22% | ROA | -3.51% | Short Interest | 2.02M | Perf YTD | -1% |
| Book/sh | 15.41 | P/C | 4.41 | EPS past 3/5Y | 31.36% -8.93% | ROE | -4.2% | 52W High | -13.03% ($44.28) | Perf Year | 62.22% |
| Cash/sh | 8.73 | P/FCF | - | Sales past 3/5Y | 35.94% 40.6% | ROIC | -3.86% | 52W Low | 117.3% ($17.72) | Perf 3Y | 194.87% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -100.37% | Gross Margin | 74.13% | Volatility(W/M) | 5.16% 5.19% | Perf 5Y | -38.24% |
| Dividend TTM | - | EV/Sales | 2.65 | Sales Y/Y TTM | 3.18% | Oper. Margin | -8.99% | ATR (14) | 1.7 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.85 | EPS Q/Q | -144.28% | Profit Margin | -5.43% | RSI (14) | 67.53 | Recom | 1.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.04 | Sales Q/Q | 20.14% | SMA20 | 13.24% ($34.01) | Beta | 1.01 | Target Price | $46.7 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/11/5 | SMA50 | 12.82% ($34.13) | Rel Volume | 1.82 | Prev Close | $36.68 |
| Employees | 883 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | 82.8% 20.07% | SMA200 | 34.91% ($28.54) | Avg Volume(3M) | 0.40M | Price | $38.51 |
| IPO | 2019/7/25 | Option/Short | Yes/Yes | Trades | 7379 | Volume | 723,385 | Change | 4.99% |
🧬 Castle Biosciences is a US-based molecular diagnostics company specializing in oncology. It offers proprietary gene expression test panels for diseases where clinical decision-making is particularly challenging, including skin cancers and other cutaneous tumors, uveal melanoma, and Barrett's esophagus. The core value proposition is helping physicians more accurately predict treatment direction and recurrence risk based on test results.
Over the past 1 year, on the higher side
13% below its 1-year high.
Traded more than usual. That is 182% of its average volume.
Next earnings report: November 5
6 days to go.
CSTL has a sound balance sheet but weak earning power
Of every $100 in sales, $8.99 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -50.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $329. Peers typically go for $458.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -38.2%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 91.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #30 of 44 in the industry
Based on market cap of $1B.
WGS#26 GeneDx Holdings Corp $2B PER - 
PSNL#27 Personalis Inc $2B PER - 
FRNM#28 Freenome Inc $1B PER - 
OPK#29 Opko Health Inc $1B PER - CSTL#30 Castle Biosciences Inc $1B PER - 
FAQ
What kind of company is CSTL?
CSTL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CSTL?
The market cap of CSTL is approximately $1.2B, ranking 2,469 within its sector.
What is the 52-week high and low for CSTL?
CSTL has recorded a 52-week high of $44.28 and a low of $17.72.
